The Importance of Antihypertensive and Lipid-Lowering Therapy in the Treatment of Patients with a New Coronavirus Infection COVID-19
At the end of 2020, a new term “post-COVID-19 syndrome” appeared in the medical community. The prevalence of this syndrome reaches more than 30% among patients who have had COVID-19, and its duration can vary from 12 weeks to 6 months. One of the most severe consequences of COVID- 19 is the defeat o...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Stolichnaya Izdatelskaya Kompaniya
2021-05-01
|
| Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
| Subjects: | |
| Online Access: | https://www.rpcardio.com/jour/article/view/2412 |